Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262310 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TDP1ALOX15TSHR | |
| SCHEMBL1260752 | 0.77 | ALDH1A1 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL1262250 | 0.76 | TSHR (0.31) | ALDH1A1ALOX15TSHR | |
| SCHEMBL1786228 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHR | |
| SCHEMBL16052611 | 0.74 | ALOX15 (0.31) | ALOX15TSHR | |
| SCHEMBL1262418 | 0.72 | ALDH1A1 (0.41) | ALDH1A1TDP1ALOX15TSHR | |
| Acetone SCHEMBL6251480 | 0.72 | CA1 (0.39) | ALDH1A1TDP1ALOX15TSHR | |
| SCHEMBL1787215 | 0.72 | ALDH1A1 (0.41) | ALDH1A1TDP1TSHR | |
| SCHEMBL1783887 | 0.72 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHR | |
| SCHEMBL1783226 | 0.71 | ALDH1A1 (0.44) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7880038-B2 | complexing a tungsten boride and molybdenum boride, a phosphate compound, Mo and W metal, hydrogen peroxide and an amine oxide to form a catalyst, reacting an olefin with H2O2 in the pH 0 to 2 or more, in presence of above catalyst to produce carbonyl compounds by oxidative breaking of C-C bond of olefin | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-1618953-B1 | USE OF A METAL CATALYST | SUMITOMO CHEMICAL CO (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20060211891-A1 | Metal catalyst and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1618953-A1 | METAL CATALYST AND ITS USE | Sumitomo Chemical Company, Limited (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1188735-B1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL CO (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040152592-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMTED | 2004-08-05 | — | — | US | disclosed |
| US-6703528-B2 | CATALYTIC OXIDATION OF OLEFIN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-09 | — | — | US | disclosed |
| WO-2003066559-A1 | PROCESS FOR PRODUCTION OF ALDEHYDES AND KETONES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-08-14 | — | — | WO | disclosed |
| EP-1188735-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-20020025906-A1 | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211891-A1 | Metal catalyst and its use | SOD1, NOX4, MVD | ALDH1A1 4428/4885TDP1 2441/4885ALOX15 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.